Oncotarget is a United States Oncology Journal created in 2010. For seven years, Oncotarget has been providing readers across the globe with the latest information dwelling on topics like Neuroscience, Pharmacology, Cardiology, Cell Biology, and Metabolism among many others. With Oncotarget being a free access journal, people interested in matters Oncology have found a reliable platform where they can read validated and well-researched information at no charge.
Since its inception, the journal has also prioritized information centering on cancer and aging. With Oncotarget being a highly sought after editorial, it now features on the SCImago Journal & Country Rank. Nationally, Oncotarget has taken the number 66 spot, a testament to the journal’s reliability. Since 2011, Oncotarget has been experiencing an upward trajectory in the number of views based on its size independent prestige indicator. Over the years, information from Oncotarget journals has become a reference point for many scholars across the globe, with 61% being the average number through which sources from the American Oncology editorial have gotten cited.
From 2011, the number of individuals citing sources from Oncotarget journals has increased by a large margin with the tally averaging 3700 sources annually. At the moment, Oncotarget has gained international acceptance because it has since day one provided valuable and relevant information to researchers and readers across the globe. Some of the notable journals that Oncotarget has created over time include CANcer-specific Evaluation System, Blockade of potassium ion transports enhances hypotonicity-induces cytocidal effects in gastric cancer, and Extracellular sphingomyelinase activity impairs TNF-a-induced endothelial cell death via ADAM17 activation and TNF receptor 1 shedding among many others.
Past and present statistics show that Oncotarget has been gaining fame annually, mainly because of providing a reliable platform for validated information. Through Oncotarget, people have since 2010 been in the know on what goes on in the healthcare world, with a proper emphasis getting placed on cancer and aging. To a large extent, Oncotarget has helped scientists advance their research and cures for particular diseases have gotten discovered in the process. Thus, Oncotarget has ultimately helped revolutionize global health standards.
To know more click here
JeanMarie Guenot is a successful business executive who has been working in the biotechnology and pharmaceutical industry for more than 20 years. Throughout her career, she has interacted with both private, and public pharmaceutical companies. She has also worked for business development, venture capital, and commercial development companies. Dr. Guenot is renowned for building an ophthalmic start-up known as SKS Ocular. The start-up focused on developing ocular drug delivery solutions. It also focused on ocular inflammation, macular degeneration, and glaucoma therapeutics. Her experience in creating and managing companies was the contributing factor to SKS Ocular’s success.
Shanghai-based Hoffmann-La Roche appointed Jeanmarie Guenot as the business advisor for one year. She began her professional career as a venture capital investments manager for Atlas Venture. JeanMarie Guenot also served on the company’s board of directors at the same time. Her scientific career commenced after she was employed as the principal scientist for Hoffmann-La-Roche’s R&D.
As a physical and medicinal chemistry graduate, she focused on several semi-empirical and quantum mechanical methods. Jeanmarie applied these methods in drug design, NMR refinement, and protein structure prediction. Before working for the company, she has served as PDL BioPharma’s VP of Corporate & Business Development. She also facilitated alliance management, mergers, and acquisitions for R&D, which is a subsidiary of PDL BioPharma. One of her notable career achievements is when she advocated for the commercialization and development of Idec-PDL50:50. The drug was developed for autoimmune diseases and Phase 2 cancer. This work earned her an Innovative Bio-Partnering Award from the BioBusiness Network.
In 2006, the Licensing Executives Society awarded her a Deal of Distinction for her pharmaceutical innovations. Consequently, in 2008, she successfully acquired the product rights of her innovation known as PDL-Biogen. The product rights stated that she developed the drug in partnership with an ophthalmology company known as Ophthotech.
Executive Committee Roles
PDL appointed her as a member of its Portfolio Management Committee and Executive Team. Her roles involved providing strategic planning insights on the commercialization of Biogen Idec-PDL. She served in PDL’s Portfolio Management Committee because of her expertise on ophthalmic, cardiovascular, and autoimmune diseases.